olivLaw · US equity research
Burning Rock Biotech Limited BNR
Services-Medical Laboratories · SIC 8071 · Vertical: Services-Medical Laboratories (SIC 8071)
Burning Rock Biotech is a China-based company that describes itself as the country's leading NGS-based cancer therapy selection company and develops early cancer detection tests. In its latest reported year, revenue edged up while the net loss narrowed substantially after several years of large losses.
The AI analysis may be outdated: new filings came after its sources (see the «AI analysis» section).
At the close of 05 Nov 2026, Burning Rock Biotech Limited (BNR) stock was 13.25 USD (+3.27% on the day), with market capitalisation 0 USD, beta 1.21, 52-week range 7.04–41.06 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 51.8
- neutral
- Bollinger (20, 2)
- 9.60 – 16.04
- in the upper half of the band · %B 0.57 · band width 50.2%
- SMA 50 / 200
- 13.38 / 16.05
- downtrend (price < SMA50 < SMA200)
- MACD (12, 26, 9)
- -0.64 / -0.63
- MACD below signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −17.8% | −5.9% | −11.8 pp | — |
| 3 months | +49.2% | −4.6% | +53.8 pp | — |
| 6 months | −20.1% | +0.2% | −20.3 pp | — |
| Year to date | −34.2% | +7.4% | −41.7 pp | — |
| 1 year | +8.6% | +8.2% | +0.4 pp | −5.8% |
| 3 years | +31.2% | +68.4% | −37.2 pp | +37.4% |
| 5 years | −91.0% | +56.5% | −147.5 pp | — |
Price returns, dividends excluded.
Quarterly results
ESEF annual reports carry no quarters: the results are annual (below).
E/P over time
EPS unavailable in the issuer's structured filings (e.g. a partnership reports per unit, not per share).
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | 65.9 m | 79.7 m | 81.7 m | 75.7 m | 70.7 m | 77.2 m |
| Revenue YoY | unavailable | +21.0% | +2.5% | −7.3% | −6.6% | +9.2% |
| Net income | -62.4 m | -125.0 m | -140.8 m | -92.1 m | -47.5 m | -7.9 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| net % | -94.7% | -156.9% | -172.4% | -121.6% | -67.2% | -10.3% |
| Free cash flow | -20.5 m | -107.1 m | -75.2 m | -37.2 m | -13.4 m | -4.8 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 68.4 m USD
- Financial debt
- unavailable USD
- Net debt
- unavailable USD
- Equity
- 76.5 m USD
- Total assets
- 117.3 m USD
- Debt / equity
- unavailable
- Current ratio
- 2.99x
- ROE
- -10.1%
- ROA
- -6.6%
- FCF margin
- -6.2%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 65.9 m | 79.7 m | 81.7 m | 75.7 m | 70.7 m | 77.2 m | SEC (XBRL)· 28 Apr 2026verified |
| Cost of revenue | 17.8 m | 22.6 m | 26.6 m | 24.5 m | 21.0 m | 19.5 m | SEC (XBRL)· 28 Apr 2026verified |
| Gross profit | 48.1 m | 57.1 m | 55.1 m | 51.2 m | 49.6 m | 57.6 m | SEC (XBRL)· 28 Apr 2026verified |
| Research & development | 40.5 m | 57.7 m | 61.2 m | 48.9 m | 31.8 m | 23.8 m | SEC (XBRL)· 28 Apr 2026verified |
| Operating income | -63.2 m | -125.1 m | -142.1 m | -94.3 m | -49.0 m | -7.8 m | SEC (XBRL)· 28 Apr 2026verified |
| Depreciation & amortisation | 5.1 m | 7.5 m | 18.0 m | 18.8 m | 7.2 m | 3.1 m | SEC (XBRL)· 28 Apr 2026verified |
| EBITDA | -58.1 m ≈ | -117.6 m ≈ | -124.2 m ≈ | -75.5 m ≈ | -41.8 m ≈ | -4.7 m ≈ | SEC (XBRL)· 28 Apr 2026derived |
| Interest expense | 102.0 k | 241.0 k | — | — | — | — | SEC (XBRL)· 29 Apr 2022verified |
| Pre-tax income | -62.4 m | -124.9 m | -140.5 m | -91.7 m | -46.7 m | -7.7 m | SEC (XBRL)· 28 Apr 2026verified |
| Income tax | 0 | 141.0 k | 288.0 k | 336.0 k | 806.0 k | 223.0 k | SEC (XBRL)· 28 Apr 2026verified |
| Net income | -62.4 m | -125.0 m | -140.8 m | -92.1 m | -47.5 m | -7.9 m | SEC (XBRL)· 28 Apr 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 290.5 m | 224.6 m | 131.3 m | 86.6 m | 71.2 m | 68.4 m | SEC (XBRL)· 28 Apr 2026verified |
| Receivables | 13.5 m | 14.5 m | 15.9 m | 17.9 m | 20.8 m | 24.3 m | SEC (XBRL)· 28 Apr 2026verified |
| Inventories | 10.4 m | 19.3 m | 18.9 m | 9.7 m | 8.6 m | 6.9 m | SEC (XBRL)· 28 Apr 2026verified |
| Current assets | 386.8 m | 285.7 m | 182.5 m | 124.5 m | 106.4 m | 105.6 m | SEC (XBRL)· 28 Apr 2026verified |
| Property, plant & equipment, net | 17.1 m | 51.1 m | 36.5 m | 18.6 m | 6.5 m | 4.4 m | SEC (XBRL)· 28 Apr 2026verified |
| Intangibles (excl. goodwill) | 530.0 k | 808.0 k | 288.0 k | 136.0 k | 58.0 k | 41.0 k | SEC (XBRL)· 28 Apr 2026verified |
| Total assets | 408.1 m | 357.6 m | 230.2 m | 146.5 m | 121.3 m | 117.3 m | SEC (XBRL)· 28 Apr 2026verified |
| Accounts payable | 5.4 m | 9.9 m | 7.4 m | 2.5 m | 4.6 m | 5.8 m | SEC (XBRL)· 28 Apr 2026verified |
| Short-term debt | 3.3 m | 0 | 0 | — | — | — | SEC (XBRL)· 20 Apr 2023verified |
| Current liabilities | 37.0 m | 58.4 m | 59.7 m | 37.1 m | 36.5 m | 35.3 m | SEC (XBRL)· 28 Apr 2026verified |
| Total liabilities | 37.1 m | 68.0 m | 62.2 m | 38.3 m | 41.7 m | 40.8 m | SEC (XBRL)· 28 Apr 2026verified |
| Equity | 371.0 m † | 289.6 m † | 167.9 m † | 108.2 m † | 79.6 m † | 76.5 m † | SEC (XBRL)· 28 Apr 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -11.3 m | -75.0 m | -66.2 m | -36.0 m | -12.6 m | -4.1 m | SEC (XBRL)· 28 Apr 2026verified |
| Capex | 9.2 m | 32.1 m | 9.0 m | 1.1 m | 742.0 k | 751.0 k | SEC (XBRL)· 28 Apr 2026verified |
| Free cash flow | -20.5 m ≈ | -107.1 m ≈ | -75.2 m ≈ | -37.2 m ≈ | -13.4 m ≈ | -4.8 m ≈ | SEC (XBRL)· 28 Apr 2026derived |
| Investing cash flow | -16.8 m | 12.8 m | -1.1 m | -1.3 m | -604.0 k | -628.0 k | SEC (XBRL)· 28 Apr 2026verified |
| Financing cash flow | 331.9 m | -8.3 m | -12.5 m | -6.9 m | -10.0 k | 272.0 k | SEC (XBRL)· 28 Apr 2026verified |
| Share repurchases | 0 | 0 | — | — | — | — | SEC (XBRL)· 29 Apr 2022verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 3 of at least 6
- score weight coverage: 18.8% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
05 Nov 2026Source: olivLaw, closing series
Market cap: 0 USD
Key indicators
Coverage and freshness
Score by group
19% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · the reported interest expense is far older than the latest period (the filer changed its XBRL tag): a stale figure is not used
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 3 of at least 6; score weight coverage: 18.8% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | -10.3% | 48 (vs peers) | 33% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | -1.9% | 0 (on a fixed band) | 44% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | 3.0x | 100 (on a fixed band) | 22% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | unavailable | unavailable | — |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet· partial100/100 · 1/3 factors with a value
- Growth· partial0/100 · 1/2 factors with a value
- Quality· partial48/100 · 1/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partialunavailable · 0/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
Burning Rock Biotech Limited (BNR). Latest full fiscal year: 2025; data up to 2025-12-31.
Figures computed from the financial statements: revenue 77.2 m USD in 2025; YoY growth 9.2%; net margin -10.3%; ROE -10.1%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 3 of at least 6; score weight coverage: 18.8% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Current ratio: 3.0x
What contradicts it
- Revenue CAGR 3Y: -1.9%
Not assessed (insufficient data or a ratio without meaning): ROIC, FCF conversion, EPS CAGR 3Y, Net debt / EBITDA, Interest coverage, P/E (TTM), EV/EBITDA, FCF yield, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Services-Medical Laboratories (SIC 8071) · same industry (4-digit SIC) · compared with 23 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| NTRANatera, Inc. | 52.7 bn | — | -10.6% | -5.7% | +35.9% | +52% / +550% |
| LHLabcorp Holdings Inc. | 29.5 bn | 29.8 | 11.4% | 6.9% | +7.2% | +35% / +67% |
| DGXQuest Diagnostics Inc | 28.0 bn | 25.4 | 15.2% | 9.5% | +11.8% | +35% / +86% |
| GHGuardant Health, Inc. | 20.8 bn | — | — | -37.9% | +32.9% | +42% / +510% |
| CAICaris Life Sciences, Inc. | 7.5 bn | 76.5 | 17.2% | 9.2% | +97.0% | +2% / unavailable |
| RDNTRadNet, Inc. | 6.1 bn | — | -2.1% | -0.9% | +11.5% | −6% / +135% |
| GRALGRAIL, Inc. | 5.4 bn | — | -17.3% | -243.8% | +17.2% | +8% / unavailable |
| CDNACaredx, Inc. | 4.0 bn | 31.9 | 33.0% | 25.9% | +13.8% | +327% / +686% |
| FTREFortrea Holdings Inc. | 2.0 bn | — | -12.3% | -2.6% | +1.0% | +61% / −31% |
| VCYTVeracyte, Inc. | 1.9 bn | 15.6 | 9.4% | 21.8% | +16.0% | −49% / −6% |
| PSNLPersonalis, Inc. | 1.7 bn | — | -62.1% | -147.7% | −17.7% | +45% / +916% |
| BLLNBillionToOne, Inc. | 1.3 bn | 116.9 | 30.2% | 11.3% | +100.0% | −14% / unavailable |
| CSTLCastle Biosciences, Inc. | 1.1 bn | — | -4.9% | -6.1% | +3.7% | −14% / +71% |
| FLGTFulgent Genetics, Inc. | 521.3 m | — | -8.6% | -27.5% | +13.8% | −37% / −32% |
| YDESYD Bio Limited | 508.3 m | — | -445.1% | -1,392.6% | +16.9% | −38% / unavailable |
| BDSXBiodesix, Inc. | 220.0 m | — | -778.9% | -25.7% | +24.1% | +140% / −33% |
| XGNExagen Inc. | 184.1 m | — | -113.8% | -26.6% | +19.7% | −4% / +313% |
| SERASera Prognostics, Inc. | 60.9 m | — | -49.7% | -34,866.7% | +5.2% | −38% / +7% |
| AMSAmerican Shared Hospital Services | 7.8 m | — | -7.5% | -5.8% | −0.9% | −45% / −51% |
| MDXHMdxhealth SA | 7.8 m | — | -2,440.4% | -31.1% | +19.8% | −96% / −95% |
| ACONAclarion, Inc. | 4.5 m | — | -74.1% | -10,260.0% | +65.6% | −75% / −100% |
| ADVBAdvanced Biomed Inc. | 3.1 m | 0.4 | 84.8% | 5,231.3% | unavailable | −77% / unavailable |
| BGLCBioNexus Gene Lab Corp. | 2.5 m | — | -33.7% | -82.4% | −21.9% | −81% / −91% |
| BNRBurning Rock Biotech Limited | 0 | — | -10.1% | -10.3% | +9.2% | +9% / +31% |
1- and 3-year price returns: for BNR from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | input data missing Total return unavailable · Per year unavailable | input data missing Total return unavailable · Per year unavailable | input data missing Total return unavailable · Per year unavailable |
| 3 years | input data missing Total return unavailable · Per year unavailable | input data missing Total return unavailable · Per year unavailable | input data missing Total return unavailable · Per year unavailable |
| 5 years | input data missing Total return unavailable · Per year unavailable | input data missing Total return unavailable · Per year unavailable | input data missing Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 28 Apr 2026; since then the company filed 6-K (10 Sept 2026), 6-K (09 Jun 2026).
In brief
Burning Rock Biotech is a China-based company that describes itself as the country's leading NGS-based cancer therapy selection company and develops early cancer detection tests. In its latest reported year, revenue edged up while the net loss narrowed substantially after several years of large losses 1.
SWOT
Strengths
- Leading position in NGS cancer testing in China, with a broad product portfolio and validation results published in top journals.
- In-hospital model generating recurring revenue from reagent sales, which creates barriers to entry for competitors.
- Proprietary library preparation technology that allows work with poor quality and low volume samples.
Weaknesses
- History of net losses, although they narrowed considerably in the latest reported year.
- Reliance on cancer therapy selection tests, which contributed almost all revenue in recent years.
- The in-hospital model requires large upfront investment and long lead times before generating revenue.
Opportunities
- Development of early detection and MRD tests could expand the market if regulatory approvals are obtained.
- Collaborations with pharmaceutical companies on companion diagnostics could add revenue.
- Expanding the network of partner hospitals could increase recurring reagent sales.
Threats
- Chinese rules on genetic data and the VIE structure could restrict operations or affect foreign investors.
- Geopolitical tension between China and the US could affect access to capital markets and partners.
- Competitors may launch similar tests faster, which could reduce market share.
Risks
- Net losseshigh
The company has reported net losses in several consecutive years and cannot assure it will achieve sustained profitability 1.
- Regulatory licensing in Chinahigh
Lack of required certificates, licences or permits could adversely affect the business 1.
- VIE structurehigh
If Chinese authorities find the contractual arrangements do not comply with law, the company could face penalties or be forced to give up its operations 1.
- Product development delaysmedium
Early detection and MRD products could be delayed or fail to obtain approvals on time 1.
- Dependence on hospitalsmedium
Relationships with hospitals and physicians are essential; changes in hospital budgets could reduce testing volumes 1.
Investment thesis
What would need to be true (bull case)
- If the in-hospital model keeps growing, recurring reagent revenue could stabilise the business and support high gross margins.
- Published clinical validations and the Breakthrough designation for an early detection test could ease adoption by hospitals and pharma partners.
- The narrower net loss in the latest year could signal a path toward profitability if the trend holds.
What would break the thesis
- If Chinese regulation tightens, operations and the contractual structure could become costlier or harder to sustain.
- The market still depends on adoption by physicians and patients, and high test costs could limit growth.
- The history of losses and heavy research spending could prolong the time before consistent profitability.
What to watch
- Number of partner hospitals under the in-hospital model and cities covered2027
- Progress on regulatory approvals for the OverC test and MRD products2027
- Development of the net loss and whether the company moves closer to profitabilityQ1 2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 28 Apr 2026; since then the company filed 6-K (10 Sept 2026), 6-K (09 Jun 2026).
The business
The company offers NGS tests for cancer therapy selection using tissue and liquid biopsy samples, plus MRD and early detection products such as OverC, which received Breakthrough Device Designation from the FDA and NMPA 1. Revenue in fiscal 2025 was RMB 539.6 million (US$ 77.2 million), and the gross profit margin reached 74.7% 1. The company still reported a net loss of RMB 55.3 million in fiscal 2025 1.
Segments
Central laboratory
The central laboratory model processes samples sent by hospitals across China and issues test reports; in fiscal 2025 it contributed 29.7% of revenue, down from earlier years, and the company describes it as a more stable business 1.
In-hospital model
The in-hospital model sets up laboratories inside hospitals and sells reagent kits on a recurring basis; the company has partnered with 94 hospitals in 43 cities and sees it as the segment with higher growth potential, contributing 41.5% of fiscal 2025 revenue 1.
Pharma and research services
Research and development services for pharmaceutical companies and hospitals, including companion diagnostics development, contributed 28.8% of revenue in fiscal 2025, up from 2023 1.
Market context
The source describes China's NGS cancer therapy selection market as at an early stage and rapidly evolving, with adoption still constrained by test costs and the scarcity of expertise to interpret results 1. The company expects the in-hospital segment to become increasingly important, and demand for early detection tests could grow if products gain approvals 1.
Trends
- Shift of testing toward hospitalsmixed
Chinese hospitals increasingly prefer in-house testing, which could favour the company's in-hospital model, although it requires large upfront investment and long implementation cycles 1.
- Adoption of early detection teststailwind
Early detection and MRD tests with high sensitivity and specificity could open new markets if regulatory approvals are obtained on time 1.
- Rapid technology and regulatory changeheadwind
The fast pace of innovation and new test launches can shorten the useful life of existing technologies, and approval requirements from the NMPA and other authorities can delay launches 1.
- Chinese rules on genetic dataheadwind
Regulations on human genetic resources in China could raise costs and delay clinical studies, especially for research activities 1.
Competitive position
The source presents the company as the clear leader in the lung cancer segment of China's NGS market and as China's largest provider of NGS cancer therapy selection tests through its central laboratory 1. Competition comes from other firms developing similar products that could launch faster, which could affect revenue 1.
- AstraZenecaAZN
Pharmaceutical partner for companion diagnostics and clinical studies, named in the source as a collaborator rather than a direct rival.
- Johnson & JohnsonJNJ
Pharmaceutical company named in the source among clinical research partners.
- Bayer
Pharmaceutical company named in the source among partners for clinical studies and central laboratory services.
- Merck KGaA
Pharmaceutical company named in the source among research collaboration partners.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Current report (foreign issuer)10 Sept 2026
- Current report (foreign issuer)09 Jun 2026
- Annual report (foreign issuer)28 Apr 2026
- Current report (foreign issuer)13 Mar 2026
- Current report (foreign issuer)23 Dec 2025
- Current report (foreign issuer)01 Dec 2025
- Current report (foreign issuer)20 Nov 2025
- Current report (foreign issuer)08 Sept 2025
- Current report (foreign issuer)06 Jun 2025
- Annual report (foreign issuer)29 Apr 2025
Sources
- [1] Form 20-F, fiscal year ended 2025-12-31 · SEC / Burning Rock Biotech Limited · 28 Apr 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.